Atypical OvCa

Question 1

Mucinous OvCa: clinical differences between expansive and infiltrative histological types: risk of stage >I:
LN metz for T1:
🔄 for s. I:
peritoneal spread:

Answer 1

risk of stage >I: 5 vs. 26%

LN metz for T1 tu: 2 vs up to 30%

risk of 🔄 for s.I: 3/75 (2 salvaged) vs 15-30%

peritoneal spread: 3 cases reported vs. 26%

Question 2

Stage IC granulosa cell tumors per MITO-9 study: N-40 median f/u 96m:
🔄rate at 96m?
5y DFS for patients on chemo and w/o?
Are they likely to die of GCT?

Answer 2

🔄rate at 96m: 35%; c/w other data

5y DFS for sIC patients on chemo and w/o:
27 vs 50% p=0.4

10y and 20y disease specific survivals for s. I GCT are 96 and 83% - it is as likely to die from alternate cause

Question 3

Granulosa cell tumor and role of composite progesterone score for prognosis - 149 pts with dx 1989-2012

Answer 3

PR composite score (>= 9), in univariate analysis, was associated with \ RFS and \OS at HR of 2.9 and 3.7 respectively

Score~staining = intensity x % of tumor

Could be confounded by DM as associated with both survival and PR expression

Question 4

Clear cell ovarian ca: Stage III/IV

Answer 4

Worse px than serous cancer (no diff sI-II)

Mortality at 12 & 24m from recurrence, vs. serous ca: 68 vs 41% and 93 vs. 73%

Median DSS s dx: 10m

CGR-R0 associated with greater benefit than in serous ca

Question 5

Clear cell ca response to chemo at recurrence?

Answer 5

10% vs. 60% for other epithelial ca subtypes